Telo Genomics Corp (OP: TDSGF )

0.1300 UNCHANGED

Streaming Delayed Price Updated: 3:07 PM EDT, Apr 29, 2024 Add to My Watchlist

Price and Volume

Volume	0
Open	0.1300
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	0.1300
Today's Range	0.1300 - 0.1300
52wk Range	0.0795 - 0.2400
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030

January 30, 2024

EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END

Via FinancialNewsMedia

Telo Genomics Completes International Standards Organization ("ISO") 15189 Final Accreditation

October 26, 2023

Toronto, Ontario--(Newsfile Corp. - October 26, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce...

Via Newsfile

Performance

YTD	-32.19%	-32.19%
1 Month	+46.23%	+46.23%
3 Month	+0.78%	+0.78%
6 Month	-15.80%	-15.80%
1 Year	-43.36%	-43.36%

More News

Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030

October 17, 2023

Via FinancialNewsMedia

Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030

January 30, 2024

From FN Media Group LLC

Via GlobeNewswire

Telo Genomics Announces Clinical Launch of Non-Invasive Cancer Diagnostic, TeloViewSMM – An Important Commercial Milestone Achieved

October 17, 2023

Via FinancialNewsMedia

Telo Genomics Presents Positive Results in Assessing MRD in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting

October 12, 2023

Via FinancialNewsMedia

Telo Genomics Announces Achieving Interim Results from Smouldering Myeloma Clinical Study

September 14, 2022

Via Newsfile

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.